Pattern Recognition Receptors and Cancer: Is There Any Role of Inherited Variation? by Anton G. Kutikhin
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
5 
Pattern Recognition Receptors and Cancer:  
Is There Any Role of Inherited Variation? 
Anton G. Kutikhin 
Kemerovo State Medical Academy 
Russian Federation 
1. Introduction 
1.1 What are pattern recognition receptors? 
The group of the pattern recognition receptors (PRRs) includes families of Toll-like receptors 
(TLRs), NOD-like receptors (NLRs), C-type lectin receptors (CLRs) and RIG-I-like receptors 
(RLRs). The summary of the most modern conceptual data about members of these families 
and about their structure and functions can be obtained from the recent comprehensive 
reviews (Elinav et al., 2011; Kawai and Akira, 2011; Osorio and Reis E Sousa, 2011; Loo and 
Gale, 2011), and the schemes of their signaling are presented in Figures 1-2.  
 
Fig. 1. The signaling of the Toll-like receptor pathway. TLR1, TLR2, TLR4, TLR5, TLR6, and 
TLR10 are usually located on the cell surface whilst TLR3, TLR7, TLR8 and TLR9 are settled 
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on the ER membrane (in the resting state) or on the endosomal/lysosomal membrane (after 
ligand stimulation and trafficking). According to the known data about their structure 
(Hashimoto et al., 1988), TLRs belong to type I transmembrane glycoproteins and contain 
three major domains (Matsushima et al., 2007). The ectodomain is oriented towards the 
extracellular space or cytoplasm (depending on receptor localization) and contains multiple 
(16-28) leucine-rich repeats (LRRs) that harbor 24–29 amino acids and may contain two 
types of motifs: typical (T) motifs (LxxLxLxxNxLxxLxxxxF/LxxLxx) and bacterial (S) motifs 
(LxxLxLxxNxLxxLPx(x)LPxx) (Bell et al., 2003; Matsushima et al., 2007). LRR modules fold 
into the parallel ǃ-sheets that bend into a concave surface, forming one or two distinct 
horseshoe structures determining the unique horseshoe shape of TLRs (Matsushima et al., 
2007). LRR hydrophobic residues are packed within the interior of ectodomain structure, 
forming a ligand-binding hydrophobic pocket (Bell et al., 2003, 2006; Kim et al., 2007; Liu et 
al., 2008). In addition, C-terminal LRRs may control the receptor dimerization and the signal 
transmission (Takada et al., 2008). The single-spanning transmembrane domain is 
homologous to IL-1R analog and anchors the receptor in the correct orientation on cell 
membrane (Huyton et al., 2007; Medzhitov et al., 1997). Third, the cytoplasmic TLR domain 
(toll/interleukin-1 receptor domain, TIR domain) is usually composed of approximately 150 
amino acid residues (Jin and Lee, 2008) and dimerizes after the ligand-ectodomain 
interaction (TLR ligands are presented in Table 1) and respective alterations in the receptor 
conformation, triggering the recruitment of the adaptor proteins (MyD88, TIRAP/MAL, 
TRIF, TRAM, SARM) to initiate the specific signaling pathway of the immune response 
stimulation (Jin and Lee, 2008; O’Neill and Bowie, 2007). It is important that all TLRs form 
hetero- or homodimers, and this feature may facilitate the dimerization of the cytoplasmic 
domain. All adaptors indicated above contain TIR domains, and interactions between such 
domains of receptor and adaptor are key for the successful signaling (Palsson-McDermott 
and O’Neill, 2007). The process of TLR signaling is mediated by a number of other adaptor 
proteins and, finally, leads to activation of NF-κB (Yamamoto et al., 2004), MAPK 
(Yamamoto et al., 2004), JNK (Takeuchi and Akira, 2001), IRF1, IRF3, IRF5, IRF7 and IRF8 
(Honda and Taniguchi, 2006) that move into the nucleus and directly or indirectly control 
the transcriptional activity of the genes encoding various proinflammatory cytokines (IL-1, 
IL-2, IL-6, IL-8, IL-10, IL-12, IL-13, IL-23, IL-27, MIP-1, MCP-1, RANTES, SOCS, IP-10, GM-
CSF, TNF-ǂ, IFN-ǂ, IFN-ǃ, IFN-Ǆ and IFN-inducible proteins (Chang, 2010; Wong et al., 
2011; Zhu and Mohan, 2010).  
Member of TLR family Exogenous ligand Endogenous ligand 
TLR1 (form heterodimers 
with TLR2) 
Triacylated lipopeptides ǃ-defensin 3 
Lipoarabinomannan 
Soluble factors of Neisseria 
meningitidis cell wall 
OspA protein of Borrelia burgdorferi 
TLR2 Lipoprotein HSP22 
Peptidoglycan HSP60 
Di- and triacylated lipopeptides HSP70 
Lipoteichoic acid HSP72 
Zymosan gp96 
Lipoarabinomannan HMGB1 
Outer-membrane porins of 
N.gonorrhoeae and S.dysenteriae 
ǃ-defensin 3 
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OspA protein of Borrelia burgdorferi Surfactant proteins A and D 
Phenol-soluble modulin of 
Staphylococcus epidermidis 
Eosinophil-derived neurotoxin 
Cell membrane glycolipids of 
Trypanosoma cruzi 
Antiphospholipid antibodies 
Hemagglutinin protein of wild-type 
measles virus 
Serum amyloid A 
Envelope proteins of HSV-1 and 
CMV 
Biglycan 
Atypical LPS of L.interrogans and 
P.gingivalis 
Versican 
Hyaluronic acid fragments 
TLR3 dsRNA mRNA 
Polyinosine-polycytidylic acid 
TLR4 Lipopolysaccharide HMGB1 
Glucuronoxylomannan Tenascin-C 
RSV fusion protein HSP60 
MMTV and MMLV HSP70 
Taxol gp96 
Mrp8 and Mrp14 
Neutrophil elastase 
Antiphospholipid antibodies 
Lactoferrin 
Surfactant proteins A and D 
ǃ-defensin-2 
Biglycan 
Low-molecular-weight 
oligosaccharide fragments of 
hyaluronan 
Fibrinogen 
Fibronectin 
Heparansulfate 
Oxidized LDL 
Saturated fatty acids 
TLR5 Flagellin  
TLR6 (form heterodimers 
with TLR2) 
Diacylated lipoprotein  
Peptidoglycan 
Zymosan 
TLR7 Imidazoquinolines Antiphospholipid antibodies 
ssRNA ssRNA 
TLR8 ssRNA ssRNA 
Antiphospholipid antibodies 
TLR9 Bacterial and viral CpG DNA IgG-chromatin complexes 
Hemozoin 
TLR10 (may form 
heterodimers with TLR1 
and TLR2) 
Unknown Unknown 
Table 1. Ligands of TLRs. Abbreviations: TLR – Toll-like receptor, HSP – heat shock protein, 
gp – glycoprotein, HSV – herpes simplex virus, CMV – cytomegalovirus, LPS – 
lipopolysaccharide, dsRNA – double-stranded RNA, HMGB1 - high mobility group box 1, 
RSV – respiratory syncytial virus, MMTV – mouse mammary tumor virus, MMLV – 
Moloney murine leukemia virus, Mrp – myeloid related protein.  
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Fig. 2. The signaling of the NOD-like receptor pathway. NLRs usually have three-domain 
structure (Chen et al., 2009). First, the C-terminal domain, contains multiple leucine-rich 
repeats (LRRs), directly recognizing exogenous and endogenous ligands (Kumar et al., 
2009). The second, central, nucleotide-binding oligomerization domain (NOD) has intrinsic 
ATPase activity and is responsible for the self-oligomerization and the formation of a 
complex after the ligand binding for the activation and recruitment of downstream signaling 
proteins (Kumar et al., 2009). These two domains are common for all known NLRs (Chen et 
al., 2009). Third, variable, the N-terminal protein-protein interaction domain, may represent 
a caspase recruitment domain (CARD), death effector domain (DED), pyrin domain (PYD), 
acidic transactivating domain, or baculovirus inhibitor of apoptosis protein repeat domain 
(BIR domain) (Kanneganti et al., 2007). The most investigated of NLRs are NOD1/CARD4 
and NOD2/CARD15. Both NOD1/CARD4 and NOD2/CARD15 recognize the components 
of bacteria cell wall: ligands of NOD1/CARD4 are Ǆ-D-glutamyl-m-diaminopimelic acid (iE-
DAP) and its synthetic derivatives (particularly having hydrophobic acyl residues) 
(Chamaillard et al., 2003; Girardin et al., 2003), and the ligand of NOD2/CARD15 is 
muramyl dipeptide (MDP) (Girardin et al., 2003). These compounds are the components of 
peptidoglycan (PGN). They can enter the cytosol through the pores formed as a result of 
bacterial toxin exposure (Ratner et al., 2007), via action of the pathogen secretion systems 
(Ratner et al., 2007), by endocytosis (Marina-Garcia et al., 2008) or by work of transporters 
(Ismair et al., 2006), and they can be released in the cytosol of infected cells during a 
bacterial cell division or from lysosomes where PGN of phagocytosed bacteria is degraded 
(Shaw et al., 2010). Until the ligand binding, LRR-containing C-terminal domain of 
NOD1/CARD4 and NOD2/CARD15 prevents the activation of the central domain (NOD) 
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and its further oligomerization (Faustin et al., 2007); ligand binding causes the 
conformational alterations in the C-terminal region that, in turn, lead to self-oligomerization 
of the central domain and to the further activation of N-terminal domain (CARD) that 
recruits and activates specific adaptor proteins, initiating NOD signaling pathways. Such 
initiation results in the activation of various transcription factors and, consequently, in the 
production of proinflammatory mediators (Inohara et al., 1999; Ogura et al., 2001).  
Although CLRs and RLRs are investigated relatively less than TLRs and NLRs, it is known 
that they recognize bacterial, viral, fungal, protozoan, and helminth PAMPs as TLRs and 
NLRs (Table 2), initiating an immune response against them through their specific signaling 
pathways (as their structure is not so clear as in the case with signaling pathways of TLRs 
and NLRs, it will be precisely depicted only in the following years). It is crucially important 
to note that in many steps signaling pathways of all classes of PRRs may intersect, making 
possible the crosstalk between them.  
 
 
 
Receptor Ligand 
MRC1 (CD206, CLEC13D, mannose 
receptor) 
High mannose, fucose 
CD207 (CLEC4K, langerin) Mannose, fucose, N-acetyl-glucosamine, ǃ-
glucan 
CD209 (CLEC4L, DC-SIGN) High mannose, fucose 
CLEC7A (Dectin-1) ǃ-1, 3 glucans 
CLEC6A (CLEC4N, Dectin-2) High mannose, ǂ-mannans 
CLEC4E (Mincle) ǂ-mannose, glycolipids, SAP130 
CLEC4A (DCIR) Mannose, fucose 
CLEC4C (BDCA-2, CD303) Mannose, fucose 
RIG-I Nucleic acids of many viruses 
MDA5 Nucleic acids of many viruses 
 
Table 2. The ligands of CLRs and RLRs.  
The receptors constituting families of PRRs are united by two general features. Firstly, 
they directly recognize common antigen determinants of virtually all classes of pathogens 
(so-called pathogen-associated molecular patterns, or simply PAMPs) and initiate 
immune response against them via specific intracellular signaling pathways. Secondly, 
they recognize endogenous ligands (since they are usually released during cell stress, they 
are called damage-associated molecular patterns, DAMPs), and, consequently, PRR-
mediated immune response can be activated without influence of infectious agents. 
Therefore, PRRs may also initiate the development of aseptic inflammation caused by 
physical factors such as mechanical pressure, thermal damage, ionizing and non-ionizing 
radiation, or chemical factors (for instance, acidic damage, alkaline damage, exposure to 
chemical war gases, croton oil or turpentine, exposure to allergens, liberation of toxic 
substances during tumor disintegration, aseptic necrosis, internal bleeding, haemolysis, 
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autoimmune processes etc.). It may promote the further progression of inflammation or, 
on the contrary, prevent the hazardous infectious complications (the combination of these 
two effects may also be true). The final outcome of PRR working is an enhanced 
production of the many proinflammatory cytokines participating in a plenty of immune 
system processes. Expression of PRRs on different levels (transcriptomic or proteomic) 
was detected in a lot of cells and organs, so it gave an evidence that these receptors 
control many elements of the complex machinery of human immune system: they allow 
epithelium and endothelium to defend against infectious agents on their own, they 
mediate the activation of adaptive immune response by antigen-presenting cells and T-
helpers, they stimulate expression of cell adhesion molecules for leukocyte rolling and for 
other processes of inflammation development, and, finally, they contribute to 
phagocytosis efficacy (Chang, 2010). As a consequence of all written above, pattern 
recognition receptors play the key role in realization of innate and adaptive immune 
response. In addition, many PRRs have a number of other vital functions apart from 
participation in the immune response realization: they may regulate various aspects of 
cell proliferation, survival, apoptosis, autophagy, reactive oxygen species generation, 
pyroptosis, angiogenesis and, consequently, of tissue remodeling and repair (Brown et al., 
2007; Fukata et al., 2006; Kim et al., 2007; Rakoff-Nahoum and Medzhitov, 2008).  
The fundamental character and diversity of PRR functions have led to amazingly rapid 
research in this field, and such investigations are very perspective for medicine as immune 
system plays a key role in vast majority if not all human diseases, and the process of 
discovering new aspects of the immune system functioning is rapidly ongoing. There is a 
plethora of papers analyzing the significance of PRRs in various diseases. One of the most 
actively exploring fields in PRR biology is their role in cancer aetiopathogenesis. Not 
surprisingly, it is (as well as tumor immunology in general) a hot spot in cancer biology as 
well.  
1.2 The position of pattern recognition receptors in cancer biology 
Since PRRs mediate immune response inducing by many immunoadjuvants (Okamoto and 
Sato, 2003; Seya, 2003), and many of them regulate immune response against potentially 
carcinogenic infectious agents (Helicobacter pylori, EBV, HPV, HHV-8/KSHV, CMV, 
Mycobacterium tuberculosis, Streptococcus pneumoniae, enteropathogenic Escherichia coli, 
Shigella flexneri, Salmonella typhimurium, Borrelia burgdorferi, Chlamydia pneumoniae, Chlamydia 
trachomatis, Chlamydia psittaci, Campylobacter jejuni, Candida spp., Schistosoma mansoni, 
Paracoccidioides brasiliensis, Histoplasma capsulatum etc.), it seems to be possible to stimulate 
anti-tumor immunity through their enhanced activation. This hypothesis, originally 
developed for the TLRs, should be also true for the all PRRs as well (Killeen and Wang, 
2006; Tsan, 2006). According to this suggestion, a reinforced PRR activation may protect 
from infectious agents and prevent, inhibit, or block carcinogenesis whilst disrupted 
functioning of these PRRs may allow infectious agents or tumor cells to avoid recognition by 
immune system and, consequently, not to be eliminated. At the same time, such PRR 
activation may promote carcinogenesis, creating a proinflammatory microenvironment (via 
action of respective cytokines) that is favorable for the tumor progression and 
chemoresistance development (Chen, 2007). It may also result in immunosuppression 
caused by chronic inflammation (Tsan, 2006). Chronic inflammation may promote the 
development of cervical, endometrial, ovarian, breast, prostate, testicular, nasopharyngeal, 
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lung, esophageal, gastric, colorectal, liver, pancreatic, gallbladder, kidney, bladder, 
lymphatic malignancies, and feasibly several other cancer types (Kinlen, 2004; Okamoto and 
Sato, 2003). In this case, on the contrary, lower PRR activity should minimize the effects of 
chronic inflammation such as enhancement of cancer initiation and promotion/progression 
and, consequently, decrease the probability of tumor development. So, the situation 
resembles a double-edged sword. The ideal variant, possibly, is the «golden mean» - the 
balance between low and high PRR activity. This hypothesis, developed for PRRs, may also 
be successfully projected on PRR intracellular signaling pathways – if their elements are 
overexpressed/constantly activated, it may lead to similar consequences as enhanced PRR 
activation. On the other hand, if the members of PRR pathways are 
underexpressed/inactivated/unable to do their work at the right time in the right place, it 
may result in the same effects that arise after decreased PRR activity, and the analogical 
«golden mean» in functioning of all genes encoding proteins constituting PRR signaling 
pathways will be the optimal variant. 
1.3 Structural genomic variation and its relevance to cancer 
The novel approaches in healthcare move towards the model of “personalized medicine”. 
Advances in the healthcare service grow annually as well as their social relevance. 
Diagnostic tests and target therapy have become a part of our life. However, in spite of the 
neoteric improvements of the screening and treatment modalities, the prognosis of patients 
with many diseases including cancer remains poor. Thus, modern molecular biology and 
medicine are concerned on the developing of more and more new genomic markers that 
possess predictive, therapeutic, or prognostic significance. Several markers may evaluate 
predisposition of any person to one or another disease with a certain degree of accuracy 
based on the results of a simple blood test. The widespread application of these tests can 
reveal the risk groups in populations, and thereafter, the complex of preventive measures 
among the risk group subjects may be conducted. Moreover, above-mentioned genomic 
markers can be identified in the perinatal period, so the choice between “include” or “not to 
include” in the risk group on their basis can be made maximally early, and, consequently, 
the preventive measures can have the greatest efficacy. As a result, the integrative systems 
of predictive genomic markers, defined once, will allow to create the programs of cancer 
prevention based on them and will permit next generations to be informed and forewarned 
about their risks and predispositions to certain diseases. 
Thereby, the discovery and development of predictive, therapeutic, or prognostic markers is 
the primary problem of biomedicine at the present time. However, the critical barrier for 
progress in this field is that it is not always easy to find an effective genomic marker that is 
exactly associated with a particular disease. One of the most widespread and important 
markers is the type of genomic markers called single nucleotide polymorphisms (SNPs). 
They represent a variation in the DNA sequence, when a single nucleotide differs between 
members of a biological species or paired chromosomes in an individual. The finishing of 
Human Genome Project and the widespread distribution of genotyping technologies have 
led to the enormous number of studies devoted to the association of the inherited gene 
polymorphisms with various diseases. The SNPs may result in amino acid substitutions 
altering protein function or splicing, and they can also change structure of enhancer 
sequences during splicing (Lamba et al., 2003) or affect mRNA stability (Tierney and 
Medcalf, 2001). SNPs may also alter transcription factor binding motifs, changing the 
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efficacy of enhancer or repressor elements (Thomas et al., 2006), and they can alter the 
structure of translation initiation codons that may lead to the downregulation of wild-type 
transcript (Zysow et al., 1995). Gene polymorphisms located in the leucine-rich repeats 
constituting ectodomain of PRRs may affect the ability of receptor to bind pathogens they 
normally recognize (Bell et al., 2003), SNPs in the transmembrane domain can lead to the 
defects of the intracellular receptor transport that do not allow to locate a receptor on the 
membrane (Johnson et al., 2007), and, finally, the polymorphisms in the internal domain 
may result in the altered interaction with the adaptor proteins or in the disrupted 
dimerization. So, inherited SNPs of the genes encoding PRRs may alter PRR expression and 
activity, modulating cancer risk and, possibly, influencing on various features of the cancer 
progression. The same statement should be true for the genes encoding proteins of PRR 
signaling pathways.  
On the basis of the fundamental and epidemiological studies, it is possible to specify the two 
fundamental mechanisms for the modulation of cancer risk by the polymorphisms of the 
genes encoding PRRs and proteins of PRR pathways. The first of them is the impairment of  
the immune response to the certain pathogens (it can be bacteria, viruses, fungi, protozoan, 
and helminths) that increase the risk of the potentially carcinogenic infection and promote 
its development along with further chronic persistence. The second mechanism is an 
increase of production of proinflammatory cytokines after the binding of the ligand 
(exogenous or endogenous) that create a condition of carcinogenic chronic inflammation.  
2. How to connect structural genomic variation in pattern recognition 
receptors and cancer? 
2.1 Relevant malignancies: the first dimension of investigation 
There is a variety of cancer types that can be associated with the inherited alterations in the 
genes encoding PRRs and proteins of PRR signaling pathways: 
 Oral cancer (the alteration of the immune response to Candida spp. and other infectious 
agents colonizing oral cavity); 
 Esophageal cancer (the variation of immune response to pathogens infecting 
esophagus); 
 Gastric cancer (on the basis of modulation of the immune response to Helicobacter pylori, 
EBV and other infectious agents potentially causing this disease); 
 Cancer of the small bowel (the modulation of the immune response to Campylobacter 
jejuni); 
 Colorectal cancer (the alteration of the immune response to many infectious agents 
inhabiting colon and rectum); 
 Liver cancer (the variation of the immune response to HBV, HCV, Helicobacter hepaticus, 
or liver flukes); 
 Gallbladder cancer (the modulation of the immune response to infectious agents 
finding in bile); 
 Pancreatic cancer (the alteration of the immune response to the pathogens inhabiting 
the pancreas); 
 Endometrial cancer (the modification of the immune response to several kinds of 
infectious agents colonizing endometrium); 
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 Cervical cancer (the alteration of the immune response to HPV and some infectious 
agents colonizing cervix); 
 Ovarian cancer (the variation of immune response to Chlamydia trachomatis); 
 breast cancer (the modulation of the immune response to some viruses infecting breast 
including HPV and EBV) 
 Prostate cancer (the variation of the immune response to Propionibacterium acnes and 
other uncertain pathogens finding in prostate tissue); 
 Testicular cancer (the modification of the immune response to EBV); 
 Kidney cancer (the variation of the immune response to bacteria and viruses infecting 
kidneys); 
 Bladder cancer (the modulation of the immune response to certain viruses or 
Schistosoma spp.); 
 Nasopharyngeal carcinoma (the alteration of the immune response to EBV); 
 Lung cancer (the variation of the immune response to Mycobacterium tuberculosis, 
Streptococcus pneumoniae, Chlamydia pneumoniae, and, possibly, to other infectious agents 
causing chronic inflammatory lung diseases); 
 Lymphoma (the modification of the immune response to EBV and many other 
infectious agents such as Borrelia burgdorferi or Helicobacter pylori); 
 Kaposi sarcoma (the variation of the immune response to HHV-8/KSHV-infection); 
 Brain tumors (the alteration of the immune response to CMV and other viruses). 
2.2 Selection of valuable polymorphisms: the second dimension of investigation 
It is important to remember that there are two main components determining the 
importance of the SNP in the programs of cancer prevention based on genomic risk markers: 
the value of odds ratio (OR) between cases and controls (as in the whole population as in 
subgroups) and the prevalence of the polymorphism in population, and they both may vary 
in different geographic regions. It is desirable to develop not the one general program, but a 
number of the individual programs for the different countries/populations/environmental 
conditions. At the moment, it is possible only to recommend a list of polymorphisms for the 
further investigation since only small number of studies with perfect design was carried out. 
The list of relevant polymorphisms that can be admitted as the most perspective for the 
further oncogenomic investigations may be created according to the following rules: 
Gene polymorphism may be included into the short list for the further oncogenomic studies if: 
 The SNP leads to the substantial functional consequences on the molecular level (for 
instance, it strongly affects transcription, splicing, translation, stability and transport of 
pre-mRNA, mRNA, non-coding RNA or protein encoding by the gene, or it noticeably 
influences signaling of synthesized protein); 
 It is associated with risk of cancer in the population studies; 
 It has any functional consequences on the molecular level and it is strongly (threshold 
OR value may be individual for each cancer type) associated with condition that 
significantly increases risk of cancer. 
 The gene polymorphism can be also included into the extended list if: 
 It is characterized by more subtle functional alterations in the gene that, however, still result 
in qualitative or quantitative alterations of the encoding protein (or non-coding RNA); 
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 It is associated only with condition that substantially increases risk of cancer but not 
with risk of cancer. 
One question may immediately arise: how to distinguish «substantial» and «more subtle» 
functional changes on the molecular level? It seems to be difficult to answer only on the 
basis of general principles of molecular biology since for one gene even the smallest 
alteration in its structure may lead to critical consequences, for another one converse 
statement can be true, and the effect also greatly depends on the position of the 
polymorphism. Therefore, an assessment of power of functional alteration should be 
individual for each gene, and although conclusions obtained in various investigations may 
differ, these discrepancies would not distort the general picture: if the polymorphism has 
«serious» functional consequences according to the results of one research, it definitely 
should be added into the short list until these conclusions will not be subverted. In any case, 
the general value of creation of such short and extended lists of the prescriptive 
polymorphisms seems to overcome difficulties related to these complications. It is important 
that many polymorphisms can be simply in the linkage disequilibrium with truly functional 
variants, and fundamental investigations are needed to determine are they only markers of 
association or indeed causal variants. All polymorphisms that are only in the linkage 
disequilibrium with functional ones should be excluded from both lists.  
In concordance with this conception, the following SNPs of the genes encoding PRRs and 
proteins of PRR signaling pathways may be accepted as the most valuable for the further 
oncogenomic investigations on the basis of the analysis of relevant published literature 
(Table 3): 
 
 
Gene Polymorphism 
TLR1-TLR6-TLR10 gene 
cluster: 
rs10008492, rs4833103, rs5743815, rs11466657 
TLR2 rs3804100, rs4696480, -196 - -174 del (Delta22), GT-microsatellite 
polymorphism 
TLR4 rs4986790, rs4986791, rs16906079, rs11536891, rs7873784, rs1927911, 
rs10759932, rs10116253, rs11536889, rs11536858 
TLR9 rs5743836, rs352140 
TIRAP/MAL rs8177400, rs8177399, rs8177374, rs7932766 
MyD88 rs1319438, rs199396 
IRAK1 rs1059703, rs3027898, rs10127175 
TRAF3 rs7143468, rs12147254, rs11160707 
TRAF6 rs331455, rs331457 
TOLLIP rs5743867 
IRF3 rs7251 
IRF5 rs2004640, rs2280714, rs10954213, 5 bp indel (CGGGG) polymorphism 
NOD1 rs2075820, ND(1)+32656 
NOD2 rs2066842, rs2066844, rs2066845, rs2006847 
MRC1 rs1926736, rs2478577, rs2437257, rs691005 
CD209 rs2287886, rs735239, rs735240, rs4804803 
CLEC7A rs16910526 
RIG-I rs36055726, rs11795404, rs10813831 
 
Table 3. The short list of polymorphisms of the genes encoding PRRs and proteins of their 
signaling pathways promising for the further oncogenomic studies.  
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The following polymorphisms of the genes encoding PRRs and proteins of PRR signaling 
pathways may be added into the extended list for the further oncogenomic investigations 
(Table 4): 
 
Gene Polymorphism 
TLR1-TLR6-TLR10 
gene cluster: 
rs4833095, rs5743551, rs5743618, rs4129009 
TLR2 rs5743704, rs62323857, rs1219178642 
TLR3 rs5743305, rs3775291, rs121434431, rs5743316 
TLR4 rs1927914, rs2149356 
TLR5 rs5744168 
TLR7 rs179008 
TLR8 rs3764880, rs2407992 
TLR9 rs352139, rs187084, rs41308230, rs5743844 
TIRAP/MAL rs7932976, rs595209, rs8177375 
MyD88 rs156265, rs7744 
IRAK1 rs1059702, rs7061789, rs2239673, rs763737, rs3027907, rs5945174 
IRAK3 rs1732886, rs1732888, rs10506481, rs1624395, rs1370128 
IRAK4 rs1461567, rs4251513, rs425155 
TRAF1 rs6920220, rs10818488, rs3761847, rs7021206 
TRAF2 rs7852970 
TRAF6 rs540386 
TOLLIP rs5743854 
IRF1 rs11242115, rs839, rs9282763 
IRF3 rs2304204, rs2304206 
IRF5 rs4728142, rs41298401, rs13242262, rs10488631, rs729302, rs3807306 
IRF7 rs1131665 
IRF8 rs17824933 
NOD1 rs72551113, rs72551107, rs6958571, rs2907749, rs2907748, rs2075822, 
rs2075819, rs2075818 
NOD2 rs104895493, rs104895476, rs104895475, rs104895474, rs104895473, 
rs104895472, rs104895462, rs104895461, rs104895460, rs104895438, 
rs5743291, rs5743260, rs2076756, rs2066843, Pro371Thr, Ala794Pro, 
Gln908His 
MRC1 rs692527, rs2477664, rs691005, rs2253120, rs2477637 
CD209 rs735240 
RIG-I rs3824456, rs669260 
MAVS/VISA/IPS-1 rs11905552, rs17857295, rs2326369, rs7269320 
Table 4. The extended list of the polymorphisms of the genes encoding PRRs and proteins of 
their signaling pathways promising for the further oncogenomic studies.  
2.3 How to organize the study: the third dimension of investigation  
The drawing-up of a rigorous study protocol is the crucial moment in the molecular 
epidemiology, and in some cases the complexity of the research is considerable. Even if 
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the investigation has a valuable aim, sufficient funding and is carried out in an excellent 
laboratory, errors in the study design may lead to the misrepresentation of the research 
results and, hence, to the reduction of their usefulness. All moments that can distort the 
study accuracy should be taken into account, and certain, the most relevant of them, are 
discussed below. Obviously, the methods of the sample collection, DNA extraction, and 
PCR conduction should be reliable enough. Modern methods such as automated DNA 
extraction, real-time PCR, and pyrosequencing should be used, although traditional 
methods such as allele-specific PCR with visualization in the agarose gel can be exploited 
as well, and their application definitely will be continued for the next decade. Anyway, 
automated methods should be of choice compared to methods where a subjective factor is 
substantial and can influence the results. The improvement of existing technologies and 
the development of new ones may elevate the accuracy of DNA extraction and PCR, 
leading to increase of validity of the results and, consequently, to the further progress in 
the field.  
Other important aspects of the study design also should be considered. To differentiate the 
impact of the chronic inflammatory conditions from the contribution of the other 
mechanisms in the association of the polymorphisms of the genes encoding PRRs and 
proteins of PRR signaling pathways with cancer risk, the stratification of cases and controls 
by infectious agent status and chronic inflammation status should be mandatory in the 
further studies devoted to this problem. The sample size should be sufficient, and it 
depends on the frequency of target polymorphism – if it is high, sample size can be less than 
in the studies where target SNP frequency is low. There is also a lack of studies investigating 
functional consequences of the polymorphisms of the genes encoding PRRs and proteins of 
PRR pathways on molecular level (for instance, alterations in the promoter activity, in the 
gene expression on the transcriptomic and proteomic levels, in stability or/and localization 
of the non-coding RNA, pre-mRNA, mRNA and protein inside the cell, in protein structure 
and functions, etc.). It is important since many polymorphisms can be simply in linkage 
disequilibrium with the other, truly functional variants, and thus such fundamental studies 
are necessary to clarify their role (are they only markers of association or indeed causal 
variants?). In addition, in certain populations replication studies should be conducted to 
prove results that were obtained in prime investigations, particularly if the sample size was 
not large.  
There are certain disparities in different population studies investigating the association of 
the polymorphisms of the genes encoding PRRs and proteins of their signaling pathways 
with various aspects of cancer development. General reasons for these discrepancies may 
include confounding host, bacterial, or environmental factors in different ethnicities 
modulating the penetrance of the variant allele and affecting risk of condition increasing 
cancer risk (such as autoimmune diseases, precancerous gastric lesions, tuberculosis, 
recurrent pneumonia etc.), different bacterial impact in aetiology of such conditions in 
different populations (that will be reflected in different features of PRR-mediated immune 
response because of specific PRR-ligand interaction), differences in the sample size, in 
age/gender/BMI/ethnicity/TNM stage/other clinicopathological characteristics between 
the study samples, in the prevalence of infectious agent (e.g. HP or EBV) in case and control 
groups, differences in diagnostics, stratification, genotyping methods, and chance. In 
addition, certain studies in which negative results were obtained could never been 
published (so-called file drawer effect) that may create a significant bias and distort a 
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picture that we can observe at the moment. Unfortunately, although some genome-wide 
association studies (GWAS) relevant to the discussing problem were performed, it is usually 
not possible to compare them with the non-GWAS on the same cancer type since there are 
no non-GWAS investigating association of the same SNPs with similar malignancies. It may 
be feasible in future when the number of studies devoted to this issue will be enough for 
correct comparative analysis.  
3. Hot spots in the field 
The most intriguing moments in the problem of the association of inherited structural 
variation in the genes encoding PRRs and proteins of PRR signaling pathways with features 
of cancer development are: 
 Are SNPs in the genes encoding PRRs or proteins of PRR signaling pathways associated 
with the features of cancer progression or only with cancer risk? Existing studies have 
shown controversial results, and the results of most of them allow to suggest that there 
is no or weak correlation between such polymorphisms and peculiarities of cancer 
progression.  
 Are the polymorphisms of the genes encoding CLRs, RLRs, or specific proteins of 
their signaling pathways associated with risk or progression of cancer? If yes, 
would be appropriate to include them in the list of polymorphisms using in 
programs of cancer risk determination and further cancer prevention? As it was 
shown above, there are some premises to think that these SNPs may be associated 
with cancer risk. Further fundamental and population studies are necessary to 
answer this question.  
 Do the polymorphisms of genes encoding PRRs or proteins of PRR signaling pathways 
(particularly TLRs and TLR pathway) correlate with altered prostate cancer risk or 
progression? Despite there are some fundamental mechanisms allowing to hypothesize 
that TLR gene polymorphisms may play a role in prostate cancer aetiology, and a 
number of comprehensive projects on large samples in various countries was 
conducted, the reliable associations of these SNPs with prostate cancer risk or with 
features of prostate cancer progression were not detected, and results vary in different 
populations. 
 Are the polymorphisms of the genes of PRR signaling pathways associated with cancer 
risk or progression to the same extent as polymorphisms of the genes encoding PRRs? It 
is logical that if SNP of gene encoding specific PRR is associated with risk or 
progression features of certain malignancies, polymorphisms in the genes encoding 
specific signaling molecules constituting pathways of this receptor should correlate 
with similar neoplasms, if they have substantial functional consequences on the 
molecular level. In contrast to the polymorphisms of the genes encoding TLRs, whose 
association with solid tumors is a subject of investigation in a lot of genetic association 
studies, the polymorphisms of the genes encoding proteins of TLR pathway are 
investigated mostly in relation to leukemia and lymphoma, and their association with 
epithelial tumors is discovered very poorly. SNPs affecting functional parts of TLR 
pathway central elements (MyD88, TRIF/TICAM1, TIRP/TRAM/TICAM2, 
TIRAP/MAL, IRAKs, TRAF3, TRAF6, TAK1, TAB1, TAB2, PKR, IRF3, IRF7) should be 
the most significant for the oncogenomic studies analyzing this problem.  
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 How the polymorphisms of the genes encoding PRRs and proteins of PRR signaling 
pathways interact with each other in relation to determination of cancer risk and 
progression? Particularly, how SNPs of positive and negative regulators of PRR activity 
(especially, miRNA) influence on cancer risk or progression if they are inherited 
together? Answers to these questions remain elusive at present time, and should be 
obtained from the fundamental and population studies in the future.  
 Which the SNPs of the genes encoding PRRs and proteins of PRR pathways have 
independent significance, and which are just in the linkage disequilibrium? Knowledge 
of it may help in listing of the polymorphisms useful in the programs of cancer risk 
determination and further prevention.  
 Which SNPs of the genes encoding PRRs and proteins of PRR pathways should be 
included in such list? Which of them have universal effect for each cancer type, and 
which influence on risk or/and progression of one cancer type but have no effect in 
relation to another malignancy? Differences in the association of the same SNP with 
different malignancies should be explained by features of specific PAMP-PRR 
interaction (probably, certain characteristics of ligand binding), or, possibly, on 
peculiarities of DAMP-PRR interaction. List of SNPs prescriptive for the further 
oncogenomic investigations may be created according to the conception suggested 
above.  
 How SNPs of the genes encoding PRRs and proteins of PRR pathways affect cancer risk 
or progression in different populations and their subgroups? How this information may 
be adjusted for application in the creation of the programs of cancer risk determination 
and further prevention? Only large, comprehensive, well-designed population studies 
may give answer to these questions.  
 Do the polymorphisms of the genes encoding PRRs and proteins of PRR pathways 
influence on cancer risk only through increase of risk of chronic inflammatory 
conditions, or they can affect it also through other mechanisms? How this information 
may be used in the programs of cancer risk determination and further prevention? To 
answer these questions, control group in population studies should include not only 
healthy controls, but also controls with the chronic inflammatory conditions 
predisposing to investigating cancer type.  
 Which infectious agents recognizing by various PRRs are carcinogenic, and which are 
not? It may help to define the cancer types associated with the SNPs of the genes 
encoding specific PRRs and proteins constituting PRR signaling pathways. 
Fundamental studies devoted to the investigation of infectious agent-PRR interactions, 
to the investigation of carcinogenicity of known infectious agents and to the discovery 
of new, possibly carcinogenic, infectious agents, should answer this question.  
No doubt, the determination of the role of SNPs in genes encoding PRRs and proteins of 
PRR signaling pathways in fields of tumor immunology and molecular epidemiology of 
cancer may open new pages in the cancer biology and cancer prevention. 
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